Literature DB >> 2953707

High pressure liquid chromatographic quantitation of teicoplanin in human serum.

J Levy, B L Truong, H Goignau, Y Van Laethem, J P Butzler, P Bourdoux.   

Abstract

A reverse phase high-pressure liquid chromatographic method to assay teicoplanin in serum is described. The procedure involves a single protein precipitation step with acetonitrile containing the internal standard mephenesin, followed by direct injection of the supernatant into the chromatograph. This HPLC method has good linearity, precision, recovery and sensitivity over the range of serum concentrations observed with the recommended dosages of the drug (5-50 mg/l). The assay has been validated by a correlation study with a bioassay on 97 sera obtained from patients treated with teicoplanin (r = 0.9519, P less than 0.001). The small serum sample size (100 microliters) and the use of a common C18 column make this assay ideal for drug monitoring, provided that HPLC equipment is available.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2953707     DOI: 10.1093/jac/19.4.533

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  4 in total

Review 1.  Clinical pharmacokinetics of teicoplanin.

Authors:  M Rowland
Journal:  Clin Pharmacokinet       Date:  1990-03       Impact factor: 6.447

Review 2.  Teicoplanin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.

Authors:  D M Campoli-Richards; R N Brogden; D Faulds
Journal:  Drugs       Date:  1990-09       Impact factor: 9.546

3.  Application of a modified bioassay for monitoring serum teicoplanin and vancomycin in febrile neutropenic patients.

Authors:  A Kureishi; P J Jewesson; K H Bartlett; C D Cole; A W Chow
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

4.  Influence of arterio-venous haemofiltration on teicoplanin elimination.

Authors:  D Hillaire-Buys; H Peyriere; E Lobjoie; J Bres; M Ossart; E Despaux
Journal:  Br J Clin Pharmacol       Date:  1995-07       Impact factor: 4.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.